Feature | May 13, 2013

CREST Sub-Study Finds Angioplasty After Carotid Stenting Reduces Risk of Repeat Blockage

Minor adjustments during carotid artery interventions can reduce long-term restenosis at two-year follow-up and may lower risk of stroke complications

May 13, 2013 — For patients who received stents to restore blood flow through the main arteries supplying blood to the brain, inflating a tiny balloon inside the arteries after implantation of the stent reduced restenosis, or repeat blockages, of the treated arteries, making them less likely to reclose. Modifying the order in which carotid stenting and balloon angioplasty is performed could also alter risk of stroke complications, according to the investigators of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) sub-study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2013 Scientific Sessions. 

CREST is the largest, prospective randomized study that compared angioplasty and stenting of the carotid artery in the neck to surgery (carotid endarderectomy), the standard treatment. Carotid stenting is currently only available as a treatment option for patients who cannot undergo surgery. The objective of this sub-study was to evaluate whether undergoing angioplasty post-carotid stenting increases the risk of complications such as stroke.

“Carotid stenting is the subject of ongoing research because it provides a less invasive treatment option, which is often necessary for patients who are too sick to undergo surgery,” said Mahmoud B. Malas, M.D., lead author of the sub-study and associate professor of surgery at Johns Hopkins University and chief of endovascular surgery at Johns Hopkins Bayview Medical Center in Baltimore. “These results show performing balloon angioplasty after stenting significantly reduced the risk of those same arteries narrowing again, but may also increase, though not significantly, the risk of stroke.”

Of 1,109 patients in CREST who underwent carotid artery stenting, 69 patients underwent balloon deployment before the stent was implanted, 344 underwent balloon deployment after the stent was implanted and 696 patients had balloon angioplasty before and after the stent was implanted.

Researchers found the risk of restenosis was reduced by 64 percent simply by expanding a tiny balloon after the stent was placed in the diseased artery rather than before it was implanted. However, the group that underwent angioplasty after the stent had a larger number of strokes compared to the group who received angioplasty only prior to the stent, but that number was not statistically significant.

Results of the CREST trial also showed historically the lowest incidence of stroke as a complication of stenting and balloon angioplasty, regardless of the order. “We actually had too few complications to make any statistically significant assessment about risk of stroke between the different ballooning methods,” explained Malas.

An estimated 83.6 million adults in the United States, about one in three, currently have some form of cardiovascular disease. An estimated 6.8 Americans are expected to suffer from stroke this year alone, according to 2013 statistics from the American Heart Association.

Balloon angioplasty is a common treatment for atherosclerosis, a hardening or narrowing of major arteries throughout the body. The carotid arteries are the main arteries supplying oxygen- and nutrient-rich blood to the brain directly from the aorta as it ascends from the heart. If these essential arteries become blocked, or stenotic, there is a higher risk of stroke because of small debris breaking off from the diseased artery and traveling to the brain. Angioplasty and stenting is performed by interventional cardiologists and vascular surgeons and involves guiding tiny instruments with medical imaging through a small incision in the groin area through major blood vessels to the affected artery—in this case the carotid arteries in the neck. Once in position, a small mesh coil called a stent is implanted inside the artery.

Malas reports no relevant conflicts of interest.

For more information: www.scai.org

Related Content

News | Cath Lab| October 09, 2015
October 9, 2015 — Cardinal Health is launching its expanded portfolio in the cardiova
Shimadzu, MIX package, Trinias Cardiovascular suites, U.S. availability

Image courtesy of Shimadzu Medical Systems

Technology | Cath Lab| October 08, 2015
Shimadzu Medical Systems USA announced the availability of the MIX package for the Trinias Cardiovascular suites. Based...
ORSIF, radiation exposure for interventionalists, greater on left side of head, Ehtisham Mahmud
Feature | Radiation Dose Management| October 06, 2015
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
Overlay Init